Recordati : Prudence est mère de sureté
>Un début d’année solide - Recordati publiait jeudi en séance ses résultats du T1 qui comme préalablement annoncés ont été positivement impactés par un effet COVID 19. La topline progresse ainsi de 12.1% à 429 M€. Celle-ci bénéficient donc d’un effet de stockage chez les grossistes et dans les officines pour un montant estimé d’environ 20 M€. Comme attendu, la croissance demeure principalement tirée par son plus important médicament Zanidip (+13.6%) ainsi que par les ...Recordati-Industria Chimica e Farmaceutica is a pharmaceutical group based in Italy. Co.'s operations are divided into two operating segments: pharmaceuticals (and pharmaceutical chemicals) and orphan drugs. Co.'s products include ZANIPRESS®/ZANEXTRA®/LERCAPREL®/LERCARIL®, an antihypertensive drug; ZANIDIP®/CORIFEO®/LERCADIP® (lercanidipine), an antihypertensive drug discovered and developed in Co.'s research laboratories; UROREC® (silodosin), a new drug indicated for the treatment of benign prostatic hyperplasia; and LIVAZO®/ALIPZA® (pitavastatin), a statin for the treatment of dyslipidemia, among others.
Oddo Securities provides securities brokerage and research services. The company offers equity, economic, and derivatives research and credit analysis services. It focuses on insurance, automotive, building materials, pharmaceuticals, telecommunications, information technology, and agri-food industries.
Unfortunately, this report is not available for the investor type or country you selected.
Browse all ResearchPool reportsReport is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.